Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities
Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities Proceedings from a webinar on October 31, 2024, moderated by Dr Neil Love. Featuring perspectives from Dr Komal Jhaveri and Dr Hope S Rugo. Published November 18, 2024. Topics: • Introduction: PI3K/AKT/PTEN Pathway and Resistance to Endocrine Therapy (0:00) • First-Line Therapy for HR-Positive Metastatic Breast Cancer (mBC) Harboring PI3K/AKT/PTEN Mutations (7:04) • Treatment Options for Recurrent mBC with PI3K/AKT/PTEN Mutations (24:11) • Beyond the Guidelines Survey (35:36) • Faculty Case Presentations (51:27) The entire program, slides, CME information, and select publications: https://www.researchtopractice.com/PI...
Presentation: Hormone Receptor-Positive Metastatic BC Harboring PI3K/AKT/PTEN Pathway Abnormalities
B7-H3 Antibody-Drug Conjugates | Oncology Today with Dr Neil Love: The Emerging Role of...
Evoque Tricuspid Intervention:Jubin Joseph, MD
Ovarian Cancer & Gastrointestinal Issues
Updates on Progressive Supranuclear Palsy(PSP) & Corticobasal Degeneration(CBD): Tale of Two Cousins
The Real Reason I Stopped Being a Surgeon
SABCS 2024: Targeting the ER and PI3K pathway - novel drugs and combinations
Can you start HRT after 60? What the evidence shows
Striving for Consensus: Optimizing the Selection and Sequencing of Therapy for Patients with Relapse
AI and the Battle for the Soul with Iain McGilchrist - Lecture 1: Information is Not Understanding
Workshop | Hepatic Encephalopathy
Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
Chichvarkin Saves Putin | Vitaly Portnikov
Can Melanoma Be Cured Even If It Spreads Widely and Metastasizes?
For Oncology Nurses: Ovarian Cancer — Proceedings from the 2026 Annual ONS Congress
Breast Cancer: Ductal Carcinoma in Situ (DCIS) EXPLAINED
Late Recurrence of Hormone Receptor-Positive Breast Cancer
Updates & Innovations in ALS Clinical Trial Landscape by Dr. Jinsy Andrews
HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review
